Surgical Science Sweden Q4 2023: Long-term high quality, short-term black box

Research Update



Redeye updates its estimates following Surgical Science’s Q4 2023 report, which featured an unusually soft end to the year that we failed to anticipate. We believe the company’s long-term equity story remains unchanged, though 2023 showed how the market has difficulty pricing the considerable sequential volatility of the company’s sales.


Christian Binder

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.